Addressing retinal hypoxia: pathophysiology, therapeutic innovations, and future prospects.

IF 2.3 Q2 OPHTHALMOLOGY
Therapeutic Advances in Ophthalmology Pub Date : 2024-09-26 eCollection Date: 2024-01-01 DOI:10.1177/25158414241280187
Bhargavee Gnanasambandam, Jacob Prince, Siddharth Limaye, Eric Moran, Ben Lee, Justin Huynh, Joseph Irudayaraj, Michael Tsipursky
{"title":"Addressing retinal hypoxia: pathophysiology, therapeutic innovations, and future prospects.","authors":"Bhargavee Gnanasambandam, Jacob Prince, Siddharth Limaye, Eric Moran, Ben Lee, Justin Huynh, Joseph Irudayaraj, Michael Tsipursky","doi":"10.1177/25158414241280187","DOIUrl":null,"url":null,"abstract":"<p><p>Retinal hypoxia stands as a pivotal yet often underappreciated factor in the etiology and progression of many retinal disorders such as glaucoma, hypertensive retinopathy, diabetic retinopathy, retinal vein occlusions, and retinal artery occlusions. Current treatment methodologies fail to directly address the underlying pathophysiology of hypoxia and aim to improve ischemia through alternative methods. In this review, we discuss the critical role of retinal hypoxia in the pathogenesis of various retinal diseases and highlight the need for innovative therapeutic strategies that address the root cause of these conditions. As our understanding of retinal hypoxia continues to evolve, the emergence of new technologies holds the promise of more effective treatments, offering hope to patients at risk of vision loss.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"16 ","pages":"25158414241280187"},"PeriodicalIF":2.3000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457288/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25158414241280187","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Retinal hypoxia stands as a pivotal yet often underappreciated factor in the etiology and progression of many retinal disorders such as glaucoma, hypertensive retinopathy, diabetic retinopathy, retinal vein occlusions, and retinal artery occlusions. Current treatment methodologies fail to directly address the underlying pathophysiology of hypoxia and aim to improve ischemia through alternative methods. In this review, we discuss the critical role of retinal hypoxia in the pathogenesis of various retinal diseases and highlight the need for innovative therapeutic strategies that address the root cause of these conditions. As our understanding of retinal hypoxia continues to evolve, the emergence of new technologies holds the promise of more effective treatments, offering hope to patients at risk of vision loss.

解决视网膜缺氧问题:病理生理学、治疗创新和未来展望。
视网膜缺氧是许多视网膜疾病(如青光眼、高血压视网膜病变、糖尿病视网膜病变、视网膜静脉闭塞和视网膜动脉闭塞)的病因和发展过程中的一个关键因素,但往往未得到足够重视。目前的治疗方法未能直接解决缺氧的潜在病理生理学问题,而是旨在通过其他方法改善缺血状况。在这篇综述中,我们将讨论视网膜缺氧在各种视网膜疾病发病机制中的关键作用,并强调需要创新的治疗策略来解决这些疾病的根本原因。随着我们对视网膜缺氧的认识不断深入,新技术的出现有望带来更有效的治疗方法,为面临视力丧失风险的患者带来希望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.50
自引率
0.00%
发文量
44
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信